Courtesy of Wikimedia Commons
Doctors may soon have a new weapon to deal with hyperthermia, one of the most dangerous (and sometimes fatal) side effects of MDMA and meth use.Eagle Pharmaceuticals has entered into an agreement with the National Institute of Health and the National Institute on Drug Abuse to begin preclinical trials in the US for Ryanodex, a pre-existing injectable drug that treats malignant hyperthermia, for use in cases of MDMA-induced hyperthermia."We are very pleased to be working alongside the NIH to explore the potential of Ryanodex to reduce elevated body and brain temperature resulting from the use of Ecstasy and Methamphetamine," said Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals, in a statement.Initial trials of Ryanodex will start this summer. Read THUMP's recent feature looking at preventive measures being taken to curtail drug deaths at music festivals here.Benjamin Boles is on Twitter.